[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334260-105":59,"doc-detail-334260-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","unlocking-cancer-vaccine-potential-what-are-the-key-factors","Unlocking cancer vaccine potential - What are the key factors?","","Cancer is a global health challenge, with changing demographics and lifestyle factors driving a growing burden worldwide. Screening advances support earlier detection, yet current cancer immunotherapies induce remission in only a limited fraction of patients and remain costly. Cancer vaccines could address these issues, but historical performance has been weak. Renewed progress stems from deeper tumor-biology understanding and vaccine-technology successes during COVID-19.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unlocking-cancer-vaccine-potential-what-are-the-key-factors/334260/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unlocking-cancer-vaccine-potential-what-are-the-key-factors/334260.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are cancer vaccines considered a promising direction for the next decade?","Question",{"text":112,"@type":113},"They may benefit from better scalability and simpler administration, and could be more effective at earlier disease stages than later ones.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do cancer vaccines differ from traditional vaccines?",{"text":117,"@type":113},"Traditional vaccines prime immunity to exogenous pathogen antigens before infection, while cancer vaccines aim to induce anti-tumor immunity against cancer antigens using an appropriate delivery vector.",{"name":119,"@type":110,"acceptedAnswer":120},"What kinds of cancer antigens are discussed in the article?",{"text":121,"@type":113},"Cancer antigens are broadly categorized into tumor-associated antigens (TAAs), tumor-specific antigens (TSAs), including neoantigens, and viral antigens.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334260,1790215750,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","HUMAN VACCINES & IMMUNOTHERAPEUTICS 2024, VOL. 20, NO. 1, 2331486 [https://doi.org/10.1080/21645515.2024.2331486](https://doi.org/10.1080/21645515.2024.2331486)  \nREVIEW  \nUnlocking cancer vaccine potential: What are the key factors?  \nMichael Granta, Lian Ni Leea, Senthil Chinnakannana, Orion Tonga, Jonathan Kwoka, Nicole Ciancib, Luke Tillmana, Abhishek Sahaa, Vinnycius Pereira Almeidac, and Carol Leungc  \naInfinitopes Ltd, Oxford, UK; bOxford Health NHS Foundation Trust, Oxford, UK; cUniversity of Oxford, Oxford, UK  \nABSTRACT  \nCancer is a global health challenge, with changing demographics and lifestyle factors producing an increasing burden worldwide. Screening advancements are enabling earlier diagnoses, but current cancer immunotherapies only induce remission in a small proportion of patients and come at a high cost. Cancer vaccines may offer a solution to these challenges, but they have been mired by poor results in past decades. Greater understanding of tumor biology, coupled with the success of vaccine technologies during the COVID-19 pandemic, has reinvigorated cancer vaccine development. With the first signs of efficacy being reported, cancer vaccines may be beginning to fulfill their potential. Solid tumors, however, present different hurdles than infectious diseases. Combining insights from previous cancer vaccine clinical development and contemporary knowledge of tumor immunology, we ask: who are the‘right’ patients, what are the ‘right’ targets, and which are the ‘right’ modalities to maximize the chances of cancer vaccine success?  \nARTICLE HISTORY  \nReceived 8 January 2024 Revised 5 March 2024 Accepted 13 March 2024  \nKEYWORDS  \nCancer vaccine; solid tumors; immunotherapy; cancer antigen; tumor biology; clinical development; oncology  \nIntroduction  \nCancer is a major contributor to human mortality and morbidity, responsible for in one in six deaths worldwide.1,2 Its burden continues to increase due to shifts in demographic trends and the influence ofglobalization on several risk factors, such as aging populations, tobacco and alcohol use, physical activity, and environmental pollution. 1,3 Technological advances, such as circulating tumor DNA (ctDNA) assaysand low-dose computed tomography (LDCT) scans, are enabling population-level screening programs to be established for progressively lower costs. With the growing impact and accessibility of screening programs globally, there is a general trend toward earlier stage diagnoses across a range of solid tumor types.4–6 Concurrently, increasingly complex cancer therapies – including antibody-drug conjugates, bioengineered cell therapies, and immune checkpoint inhibitors (ICIs)– have improved patient outcomes and survival significantly, but only for small proportions of patients.7 Moreover, the high market price of these drugs has contributed to a snowballing in the cost of cancer care and, as a result, many are inaccessible to lower resourced settings.8–10 The culmination of these trends in oncology – a growing global burden of cancer, a shift to earlier stage diagnosis, and the increasing cost of advanced therapeutics – highlights the need, specifically, for accessible treatments that are suitable for administration in the earlier stages of a cancer’s development.  \nCancer vaccines offer a potential solution to the problems facing the field of oncology in the coming decade. These therapies benefit from economies ofscale, simple administration, and may be more effective in earlier disease settings than later.11, 12 Traditional vaccines aim to prevent or ameliorate infectious  \ndiseases through priming immune responses to exogenous antigens associated with given pathogens before a natural infection occurs. The induced adaptive immune response consists of humoral immunity (mediated predominantly by antibodies and memory B lymphocytes), and cellular immunity (typically carried out by CD4+ and CD8+ T lymphocytes) . Similarly, cancer vaccines seek to induce an anti-t","cbCaig6lblgAUqhz","https://ap.wps.com/l/cbCaig6lblgAUqhz","pdf",2761449,13,"English","# Introduction\n## Cancer vaccines as a solution\n## Cancer antigens and target categories","[{\"question\":\"Why are cancer vaccines considered a promising direction for the next decade?\",\"answer\":\"They may benefit from better scalability and simpler administration, and could be more effective at earlier disease stages than later ones.\"},{\"question\":\"How do cancer vaccines differ from traditional vaccines?\",\"answer\":\"Traditional vaccines prime immunity to exogenous pathogen antigens before infection, while cancer vaccines aim to induce anti-tumor immunity against cancer antigens using an appropriate delivery vector.\"},{\"question\":\"What kinds of cancer antigens are discussed in the article?\",\"answer\":\"Cancer antigens are broadly categorized into tumor-associated antigens (TAAs), tumor-specific antigens (TSAs), including neoantigens, and viral antigens.\"}]","Unlocking cancer vaccine potential - What are the key factors? | PDF",1790006036,33]